-
Interferon regulatory factor 4 drives M2 macrophage polarization in lung adenocarcinoma via the absent in melanoma 2-mediated phosphoinositide 3-kinase/protein kinase B signaling pathwa
Author: Zou, Xiaoyun; Ji, Qing; Wen, Zhongzheng; Lei, Limei; Chen, Xuan; Hu, Wen
Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 5, pp. 343-351. DOI: 10.1097/CAD.0000000000001795
-
Eugenol as a game-changer: overcoming osimertinib resistance in non-small cell lung cancer by inhibiting glycolysis via the tripartite motif containing 59/extracellular signal-regulated kinase pathwa
Author: Zhao, Kun; Wang, Wei; Sun, Yansha; Li, Ke
Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 5, pp. 312-328. DOI: 10.1097/CAD.0000000000001793
-
Hematopoietic progenitor kinase 1 inhibitor BGB-15025 induces apoptosis in acute myeloid leukemia cells through the cell cycle pathway and mitogen-activated protein kinase/extracellular signal-regulated kinase pathway signaling axi
Author: Yang, Shiyu; Li, Fenglin; Zhuang, Haihui; Chen, Dong; Jiang, Xia; Zhou, Yanhan; Pei, Renzhi; Li, Shuangyue; Ye, Peipei; Lu, Ying
Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 5, pp. 329-342. DOI: 10.1097/CAD.0000000000001794
-
Treatment of HRD-positive elderly ovarian cancer patient: a case repor
Author: Jiang, Yuxin; Yi, Qijun; Wang, Yueer; Li, Chen; Liu, Haiyan
Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 5, pp. 352-357. DOI: 10.1097/CAD.0000000000001772
-
Inhibiting FGFR by toadflax reverses erlotinib resistance in nonsmall cell lung cance
Author: Han, Bateer; Ma, Ying; Bao, Shuguang; Gao, Hui; Gao, Yanqing; Guo, Qiang; Li, Ao; Li, Meitao; Yu, Rong; Wang, Hongwei
Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 5, pp. 301-311. DOI: 10.1097/CAD.0000000000001649
-
Multimodal treatment with thiotepa, bevacizumab, teniposide, and tunlametinib in a patient with neurofibromatosis type 1-associated oligodendroglioma: a rare case repor
Author: Zhou, Shizhen; Chen, Yanfei; Gao, Guoliang; Pan, Xueqiang; Sun, Peng; Tao, Rongjie
Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 4, pp. -. DOI: 10.1097/CAD.0000000000001786
-
Comparative efficacy and safety of S-1 plus oxaliplatin with sintilimab vs. paclitaxel-S-1-oxaliplatin and docetaxel-oxaliplatin-5-fluorouracil as first-line therapy for advanced gastric cance
Author: Wang, Yicong; Ma, Bingyang; Zhang, Chenguang; Wang, Yuwen; Pan, Ting; Zhao, Chunlong; Cai, Baojia; Yu, Pengjie; Guo, Bin; Ma, Jinfu
Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 4, pp. 253-264. DOI: 10.1097/CAD.0000000000001782
-
EP4 influences bortezomib resistance in multiple myeloma by modulating endoplasmic reticulum stress via the phosphatidylinositol 3-kinase/protein kinase B pathwa
Author: Shi, Tengfei; Chen, Yao; Liu, Zhiqiang; Liu, Aichun
Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 4, pp. 280-296. DOI: 10.1097/CAD.0000000000001792
